Daiichi's Benicar accord brings payout over drugs to US$339m
Wilmington, Delaware
DAIICHI Sankyo Inc's settlement of thousands of lawsuits blaming the company's blood pressure drugs for causing intestinal damage brings to US$339 million the amount the drugmaker has paid for its handling of the medicines.
Daiichi officials agreed on Monday to pay US$300 million to resolve patient suits over its Benicar, Benicar HCT, Azor and Tribenzor blood pressure treatments. The accord comes more than two years after the Chuo-Ku, Japan-based company paid US$39 million to resolve the US government's allegations that it paid illegal kickbacks to doctors who prescribed the medicines.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife says private placement is to address urgent cash needs
Cordlife substantial shareholders lay out separate plans to address issues after AGM
Disney, Warner Bros Discovery launch US streaming bundle
Indian winemaker Sula Vineyards' Q4 profit slips on mounting expenses
Olam tops Louis Dreyfus’ offer for Australia’s Namoi Cotton as takeover battle heats up
Puma returns to sales growth in Americas despite ‘volatile’ market